{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:56:19Z","timestamp":1791186979507,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05666-z","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:35:55Z","timestamp":1785490555000},"page":"4425-4440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UCHL1-mediated deubiquitination of PARK7 suppresses ferroptosis and enhances tumor progression in triple-negative breast cancer"],"prefix":"10.1007","volume":"481","author":[{"given":"Shaojun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"5666_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5666_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2021.39.15_suppl.572","volume":"39","author":"Y Han","year":"2021","unstructured":"Han Y, Xu S, Colditz GA, Toriola AT (2021) Trends in breast cancer mortality according to molecular subtypes: A population-based study. J Clin Oncol 39:572\u2013572. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.572","journal-title":"J Clin Oncol"},{"key":"5666_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast Cancer Treatment: A Review. JAMA 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"5666_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"5666_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171875","author":"VB Varzaru","year":"2024","unstructured":"Varzaru VB, Vlad T, Popescu R, Vlad CS, Moatar AE, Cobec IM (2024) Triple-negative breast cancer: molecular particularities still a challenge. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics14171875","journal-title":"Diagnostics"},{"key":"5666_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153697","author":"Q Wu","year":"2021","unstructured":"Wu Q, Siddharth S, Sharma D (2021) Triple negative breast cancer: a mountain yet to be scaled despite the triumphs. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13153697","journal-title":"Cancers (Basel)"},{"key":"5666_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1326023","volume":"13","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhao Q, He H, Qi Y, Bai Y, Zhao J, Yang Y (2023) TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review. Front Oncol 13:1326023. https:\/\/doi.org\/10.3389\/fonc.2023.1326023","journal-title":"Front Oncol"},{"key":"5666_CR8","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.apsb.2022.03.020","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Hua P, He C, Chen M (2022) Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine. Acta Pharm Sin B 12:3567\u20133593. https:\/\/doi.org\/10.1016\/j.apsb.2022.03.020","journal-title":"Acta Pharm Sin B"},{"key":"5666_CR9","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.freeradbiomed.2018.04.113","volume":"120","author":"F Ursini","year":"2018","unstructured":"Ursini F, Bosello-Travain V, Cozza G, Di Paolo ML, Miotto G, Rossetto M, Roveri A, Toppo S, Venerando R, Vu\u010dkovi\u0107 A-M, Zaccarin M, Maiorino M (2018) OP-12 - Lipid peroxidation and GPx4: the players of the oxygen paradox. Free Radic Biol Med 120:S33. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.04.113","journal-title":"Free Radic Biol Med"},{"key":"5666_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010449","author":"L Rochette","year":"2022","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C (2022) Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010449","journal-title":"Int J Mol Sci"},{"key":"5666_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/13880209.2024.2309891","volume":"62","author":"P Chen","year":"2024","unstructured":"Chen P, Ye Q, Liang S, Zeng L (2024) Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy. Pharm Biol 62:195\u2013206. https:\/\/doi.org\/10.1080\/13880209.2024.2309891","journal-title":"Pharm Biol"},{"key":"5666_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14417","volume":"103","author":"S Xi","year":"2024","unstructured":"Xi S, Ding W, Weng D, Zeng Y, Gao K, Wu Q, Huang G, Li Y, Yue H (2024) Chrysophanol induces apoptosis and ferroptosis of gastric cancer cells by targeted regulation of mTOR. Chem Biol Drug Des 103:e14417. https:\/\/doi.org\/10.1111\/cbdd.14417","journal-title":"Chem Biol Drug Des"},{"key":"5666_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/ijn.S292528","volume":"16","author":"X Liu","year":"2021","unstructured":"Liu X, Zhu X, Qi X, Meng X, Xu K (2021) Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy. Int J Nanomed 16:1037\u20131050. https:\/\/doi.org\/10.2147\/ijn.S292528","journal-title":"Int J Nanomed"},{"key":"5666_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030561","author":"JN Tsoporis","year":"2023","unstructured":"Tsoporis JN, Amatullah H, Gupta S, Izhar S, Ektesabi AM, Vaswani CM, Desjardins JF, Kabir G, Teixera Monteiro AP, Varkouhi AK, Kavantzas N, Salpeas V, Rizos I, Marshall JC, Parker TG, Leong-Poi H, Dos Santos CC (2023) DJ-1 deficiency protects against sepsis-induced myocardial depression. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox12030561","journal-title":"Antioxidants (Basel)"},{"key":"5666_CR15","doi-asserted-by":"publisher","first-page":"101796","DOI":"10.1016\/j.redox.2020.101796","volume":"38","author":"H Amatullah","year":"2021","unstructured":"Amatullah H, Maron-Gutierrez T, Shan Y, Gupta S, Tsoporis JN, Varkouhi AK, Teixeira Monteiro AP, He X, Yin J, Marshall JC, Rocco PRM, Zhang H, Kuebler WM, Dos Santos CC (2021) Protective function of DJ-1\/PARK7 in lipopolysaccharide and ventilator-induced acute lung injury. Redox Biol 38:101796. https:\/\/doi.org\/10.1016\/j.redox.2020.101796","journal-title":"Redox Biol"},{"issue":"1","key":"5666_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41467-020-15109-y","volume":"11","author":"J Cao","year":"2020","unstructured":"Cao J, Chen X, Jiang L, Lu B, Yuan M, Zhu D, Zhu H, He Q, Yang B, Ying M (2020) DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat Commun 11:1251. https:\/\/doi.org\/10.1038\/s41467-020-15109-y","journal-title":"Nat Commun"},{"key":"5666_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00535-023-02068-6","volume":"59","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang H, Chen L, Fu K, Yan Y, Liu Z (2024) CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation. J Gastroenterol 59:229\u2013249. https:\/\/doi.org\/10.1007\/s00535-023-02068-6","journal-title":"J Gastroenterol"},{"key":"5666_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10555-017-9702-0","volume":"36","author":"Y Fang","year":"2017","unstructured":"Fang Y, Shen X (2017) Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev 36:669\u2013682. https:\/\/doi.org\/10.1007\/s10555-017-9702-0","journal-title":"Cancer Metastasis Rev"},{"key":"5666_CR19","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.7150\/ijbs.82152","volume":"19","author":"Z Feng","year":"2023","unstructured":"Feng Z, Tao S, Huang Z, Zheng B, Kong X, Xiang Y, Zhang Q, Song H, Xu Z, Wei X, Zhao F, Chen J (2023) The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ\/NFATC1 signalling. Int J Biol Sci 19:2319\u20132332. https:\/\/doi.org\/10.7150\/ijbs.82152","journal-title":"Int J Biol Sci"},{"key":"5666_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00018-024-05186-3","volume":"81","author":"J Wang","year":"2024","unstructured":"Wang J, Ji C, Ye W, Rong Y, Ge X, Wang Z, Tang P, Zhou Z, Luo Y, Cai W (2024) Deubiquitinase UCHL1 promotes angiogenesis and blood-spinal cord barrier function recovery after spinal cord injury by stabilizing Sox17. Cell Mol Life Sci 81:137. https:\/\/doi.org\/10.1007\/s00018-024-05186-3","journal-title":"Cell Mol Life Sci"},{"key":"5666_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12957-022-02620-3","volume":"20","author":"J Yao","year":"2022","unstructured":"Yao J, Reyimu A, Sun A, Duoji Z, Zhou W, Liang S, Hu S, Wang X, Dai J, Xu X (2022) UCHL1 acts as a potential oncogene and affects sensitivity of common anti-tumor drugs in lung adenocarcinoma. World J Surg Oncol 20:153. https:\/\/doi.org\/10.1186\/s12957-022-02620-3","journal-title":"World J Surg Oncol"},{"key":"5666_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154235","volume":"240","author":"C Tian","year":"2022","unstructured":"Tian C, Liu Y, Liu Y, Hu P, Xie S, Guo Y, Wang H, Zhang Z, Du L, Lei B, Wang Y, Xue L, Zhang D, Su J, Zhang X, Zhang R, Chen J, Zhang X, Chen L, Li M, Jia Q, Song J, Liu J (2022) UCHL1 promotes cancer stemness in triple-negative breast cancer. Pathol Res Pract 240:154235. https:\/\/doi.org\/10.1016\/j.prp.2022.154235","journal-title":"Pathol Res Pract"},{"key":"5666_CR23","doi-asserted-by":"publisher","first-page":"188890","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W (2023) GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer 1878:188890. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188890","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5666_CR24","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1038\/s41467-022-33559-4","volume":"13","author":"C Grethe","year":"2022","unstructured":"Grethe C, Schmidt M, Kipka GM, O\u2019Dea R, Gallant K, Janning P, Gersch M (2022) Structural basis for specific inhibition of the deubiquitinase UCHL1. Nat Commun 13:5950. https:\/\/doi.org\/10.1038\/s41467-022-33559-4","journal-title":"Nat Commun"},{"key":"5666_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, Stockwell B, Kroemer G, Kang R, Tang D (2023) Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med 15:eadg3049. https:\/\/doi.org\/10.1126\/scitranslmed.adg3049","journal-title":"Sci Transl Med"},{"key":"5666_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-024-01772-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Chen C, Zhao C, Li T, Ma L, Jiang J, Duan Z, Si Q, Chuang TH, Xiang R, Luo Y (2024) Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct Target Ther 9:64. https:\/\/doi.org\/10.1038\/s41392-024-01772-w","journal-title":"Signal Transduct Target Ther"},{"key":"5666_CR27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s43018-025-00937-y","volume":"6","author":"L Zhou","year":"2025","unstructured":"Zhou L, Lian G, Zhou T, Cai Z, Yang S, Li W, Cheng L, Ye Y, He M, Lu J, Deng Q, Huang B, Zhou X, Lu D, Zhi F, Cui J (2025) Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity. Nat Cancer 6:768\u2013785. https:\/\/doi.org\/10.1038\/s43018-025-00937-y","journal-title":"Nat Cancer"},{"key":"5666_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/ol.2020.11948","volume":"20","author":"H Yang","year":"2020","unstructured":"Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, Chen S, Ding S, Zhong L, Guo W, Wang W (2020) Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. Oncol Lett 20:87. https:\/\/doi.org\/10.3892\/ol.2020.11948","journal-title":"Oncol Lett"},{"key":"5666_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3892\/ol.2021.12773","volume":"22","author":"M Manjunath","year":"2021","unstructured":"Manjunath M, Choudhary B (2021) Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett 22:512. https:\/\/doi.org\/10.3892\/ol.2021.12773","journal-title":"Oncol Lett"},{"key":"5666_CR30","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096280750240123054936","author":"MS Varshini","year":"2024","unstructured":"Varshini MS, Krishnamurthy PT, Reddy RA, Wadhwani A, Chandrashekar VM (2024) Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer. Curr Cancer Drug Targets. https:\/\/doi.org\/10.2174\/0115680096280750240123054936","journal-title":"Curr Cancer Drug Targets"},{"key":"5666_CR31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.Ccr-19-1373","volume":"26","author":"S Liu","year":"2020","unstructured":"Liu S, Gonz\u00e1lez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le D\u00e9v\u00e9dec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal ACO, Ovaa H, Zhang L, Martens JWM, Ten Dijke P (2020) Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGF\u03b2-induced breast cancer metastasis. Clin Cancer Res 26:1460\u20131473. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1373","journal-title":"Clin Cancer Res"},{"key":"5666_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101381","volume":"5","author":"S Liu","year":"2024","unstructured":"Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T (2024) UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med 5:101381. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101381","journal-title":"Cell Rep Med"},{"key":"5666_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010118","author":"SY Kwan","year":"2020","unstructured":"Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, Lu KH (2020) Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) promotes uterine serous cancer cell proliferation and cell cycle progression. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12010118","journal-title":"Cancers (Basel)"},{"key":"5666_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/cas.14236","volume":"111","author":"X Li","year":"2020","unstructured":"Li X, Hattori A, Takahashi S, Goto Y, Harada H, Kakeya H (2020) Ubiquitin carboxyl-terminal hydrolase L1 promotes hypoxia-inducible factor 1-dependent tumor cell malignancy in spheroid models. Cancer Sci 111:239\u2013252. https:\/\/doi.org\/10.1111\/cas.14236","journal-title":"Cancer Sci"},{"key":"5666_CR35","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1021\/acs.biochem.9b01076","volume":"59","author":"CS Hewitt","year":"2020","unstructured":"Hewitt CS, Krabill AD, Das C, Flaherty DP (2020) Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinases. Biochemistry 59:3447\u20133462. https:\/\/doi.org\/10.1021\/acs.biochem.9b01076","journal-title":"Biochemistry"},{"key":"5666_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101987","volume":"45","author":"J Cheng","year":"2024","unstructured":"Cheng J, Liu H, Shen Y, Ding J, He H, Mao S, Chen L, Zhang C, Zhou J (2024) Deubiquitinase UCHL1 stabilizes KDM4B to augment VEGF signaling and confer bevacizumab resistance in clear cell renal cell carcinoma. Transl Oncol 45:101987. https:\/\/doi.org\/10.1016\/j.tranon.2024.101987","journal-title":"Transl Oncol"},{"key":"5666_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13058-024-01800-1","volume":"26","author":"J Li","year":"2024","unstructured":"Li J, Liang Y, Zhou S, Chen J, Wu C (2024) UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. Breast Cancer Res 26:44. https:\/\/doi.org\/10.1186\/s13058-024-01800-1","journal-title":"Breast Cancer Res"},{"key":"5666_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051256","author":"W Jin","year":"2020","unstructured":"Jin W (2020) Novel insights into PARK7 (DJ-1), a potential anti-cancer therapeutic target, and implications for cancer progression. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9051256","journal-title":"J Clin Med"},{"key":"5666_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 18:280\u2013296. https:\/\/doi.org\/10.1038\/s41571-020-00462-0","journal-title":"Nat Rev Clin Oncol"},{"key":"5666_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.892957","volume":"9","author":"C Qu","year":"2022","unstructured":"Qu C, Peng Y, Liu S (2022) Ferroptosis biology and implication in cancers. Front Mol Biosci 9:892957. https:\/\/doi.org\/10.3389\/fmolb.2022.892957","journal-title":"Front Mol Biosci"},{"key":"5666_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206007","volume":"10","author":"J Pan","year":"2023","unstructured":"Pan J, Xiong W, Zhang A, Zhang H, Lin H, Gao L, Ke J, Huang S, Zhang J, Gu J, Chang ACY, Wang C (2023) The imbalance of p53-Park7 signaling axis induces iron homeostasis dysfunction in doxorubicin-challenged cardiomyocytes. Adv Sci 10:e2206007. https:\/\/doi.org\/10.1002\/advs.202206007","journal-title":"Adv Sci"},{"key":"5666_CR42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2022.12.005","volume":"55","author":"S Chen","year":"2023","unstructured":"Chen S, Xia H, Sheng L (2023) WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. Dig Liver Dis 55:967\u2013981. https:\/\/doi.org\/10.1016\/j.dld.2022.12.005","journal-title":"Dig Liver Dis"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05666-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:45:01Z","timestamp":1791186301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05666-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5666"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05666-z","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided their consent, and the study was approved by the Ethics Committee of Shenzhen Maternity and Child Healthcare Hospital (Approval No.: SFYLS [2025] 051), adhering to the Helsinki\u2019s Declaration.\u00a0All animal research protocols were approved the Institutional Animal Care and Use Committee of Shenzhen Maternity and Child Healthcare Hospital (Approval No.: SZMCHH 21-2502-6), aligning with the \u201cGuidelines for the Care and Use of Laboratory Animals\u201d.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}